MULTIFOCAL MOTOR NEUROPATHY (MMN)
Clinical trials for MULTIFOCAL MOTOR NEUROPATHY (MMN) explained in plain language.
Never miss a new study
Get alerted when new MULTIFOCAL MOTOR NEUROPATHY (MMN) trials appear
Sign up with your email to follow new studies for MULTIFOCAL MOTOR NEUROPATHY (MMN), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug TAK-771 aims to control rare nerve diseases in japanese patients
Disease control OngoingThis study tests a drug called TAK-771 in 26 Japanese adults with two rare nerve conditions (CIDP and MMN) that cause weakness and disability. The goal is to see if the drug is safe and helps control symptoms over up to 45 months. Participants receive the drug every 2 to 4 weeks …
Matched conditions: MULTIFOCAL MOTOR NEUROPATHY (MMN)
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated May 26, 2026 06:38 UTC
-
New hope for rare nerve disorder: Long-Term drug trial underway
Disease control OngoingThis study is a long-term follow-up for adults with multifocal motor neuropathy (MMN), a rare condition that causes progressive muscle weakness. It tests the safety and effectiveness of a drug called ARGX-117, given intravenously. Participants who completed an earlier trial can j…
Matched conditions: MULTIFOCAL MOTOR NEUROPATHY (MMN)
Phase: PHASE2 • Sponsor: argenx • Aim: Disease control
Last updated May 26, 2026 06:37 UTC
-
New drug aims to replace IVIg for nerve disease
Disease control OngoingThis study tests if a new medicine, empasiprubart, works as well as standard IVIg for adults with multifocal motor neuropathy (MMN), a condition that causes muscle weakness. About 154 people who have responded to IVIg in the past will receive either empasiprubart or IVIg for up t…
Matched conditions: MULTIFOCAL MOTOR NEUROPATHY (MMN)
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated May 26, 2026 06:31 UTC